+34 620 10 75 37info@nanbiosis.com

About us

Nanbiosis

The Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and the Jesus Usón Minimally Invasive Surgery Center (JUMISC) have been working together since 2010 in different research projects due to the synergies and the complementarity between their platforms. In November 2011, and after a successful career in developing collaborative research projects, the managers of both institutions met in order to study and assess new lines of work. The result was the signing of a scientific and technological cooperation agreement, with the objective of combining efforts and achieving a better planning of the research services and platforms of both institutions.

In this context, the Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine (NANBIOSIS) arises from a joint initiative of the CIBER-BBN and the JUMISC.

These two centers group 27 complementary and coordinated units (7 from the JUMISC and 20 form the CIBER-BBN), located in different institutions, which in turn are distributed through 5 Autonomous Communities: Aragon, Cataluña, Extremadura, Madrid , País Vasco and Valencia.

NANBIOSIS is organized in five platforms:

  • Production of Biomolecules,
  • Production of Biomaterials and Nanomaterials,
  • Preclinical Validation-Tissue, Biomaterial and Surface Characterization,
  • Preclinical Validation-Bioimaging, and
  • High Performance Computing.

Each platform is constituted by one or more units, which are distributed through the Spanish geography: one in Alava, one in Badajoz, thirteen in Barcelona, seven in Cáceres, two in Madrid, one in Valencia and three in Zaragoza. This infrastructure provides high technological resources and high qualified personal, and offers open services to the scientific community.

NANBIOSIS provides a complete service that includes the design and production of biomaterials and nanomaterials and their nanoconjugates, and the characterization of these bio-/nanomaterials, tissues and medicals devices from a physic-chemical, functional, toxicological and biological (including preclinical validation) point of view, focused also on biomedical applications such as: IVDs, biosensors, regenerative medicine, drug delivery, therapeutic agents or MRI contrast agents and medical devices. A Unit dedicated to high performance computing is also included for those technological applications with large scale computational demand.

Although the essence of its singularity and strategic importance of NANBIOSIS lies basically in the centralized structure, many of the units are by themselves already unique in their kind and the Head Investigators who are the scientific coordinators of the different units are among the best Spanish researchers in the areas integrated in the sphere of activity of the ICTS.

The coordination of the required units for the development of the project is offered under a “Single Contact Point” model for either subcontracting or collaboration. This allows our groups to participate in competitive calls, e.g. H2020, under the umbrella of NANBIOSIS like one only partner.